Target intelligence / Profile preview

O-antigen of Shigella flexneri serotype 2a

Molecular classification
Other (Bacterial cell surface polysaccharide antigen), Bacterial surface antigen, Component of lipopolysaccharide (LPS)
01

Overview

The O-antigen of Shigella flexneri serotype 2a is a serotype-specific, highly immunogenic polysaccharide that constitutes the outermost domain of the bacterium’s lipopolysaccharide (LPS) layer[1][2][5]. It consists of a repeating tetrasaccharide unit, typically containing three L-rhamnose residues and one N-acetylglucosamine (GlcNAc), with critical modifications such as glucosylation and O-acetylation defining subtype-specific epitopes[1][2]. The O-antigen is the primary determinant of immune recognition and serotyping for Shigella flexneri, playing a key role in the induction of protective antibody responses as well as resistance to complement-mediated killing[1][2][5]. The structure provides a molecular basis for serotype 2a identification and underpins vaccine strategies, as targeting this antigen can confer serotype-specific immunity[4][6]. The O-antigen also serves as a receptor for certain bacteriophages and can influence virulence by modulating outer membrane stability and host cell invasion mechanisms[1][3]. The high variability and capacity for serotype conversion present both challenges and opportunities in disease control, vaccine design, and diagnostic approaches[5][6].

Other names
O-specific polysaccharide of Shigella flexneri 2aO-polysaccharide of S. flexneri 2aShigella flexneri 2a O-antigenS. flexneri 2a O-antigen
02

Mechanism of action

Antibodies bind to O-antigen, neutralizing bacteria and enhancing opsonization[4] Vaccines elicit O-antigen-specific immune responses, providing serotype-specific protection[4] Polysaccharide-based immunization induces functional antibodies, leading to bacterial killing by complement[6]

03

Biological functions

Immune response inductionSerotype determinationProtection against complement-mediated killingModulation of bacterial invasion and virulenceBacteriophage receptor function
04

Disease associations

Infection (Central to pathogenesis of shigellosis)Immune evasionAntigenic diversity for vaccine targeting
05

Safety considerations

Serotype specificity: O-antigen diversity limits cross-protection in vaccine development[6]Potential for antigenic variation and serotype conversion to evade immune responses[2][5][6]
06

Interacting drugs

Monoclonal antibodies (e.g., F22-4)

2 more in the full profile.

07

Biomarkers

O-antigen structure (used for serotyping in diagnostic work)O-antigen-specific IgG titers (pharmacodynamic marker for candidate vaccines)[4][6]

Beyond the preview

Go deeper on O-antigen of Shigella flexneri serotype 2a.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on O-antigen of Shigella flexneri serotype 2a.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call